MELAB3 THE LAUNCH OF THE YEAR OF THE ROCHE POSAY
Health
MELAB3 THE LAUNCH OF THE YEAR OF THE ROCHE POSAY
Sep 26, 2024
La Roche Posay, one of our most recognized consumer brands in the dermocosmetic market, launched its innovation MELAB3.
MELAB3 improves skin hyperpigmentation thanks to its multi-patented molecule Melasyl that controls and prevents all pigmentation disorders, including melasma, solar lentic and post-inflammatory hyperpigmentation (PIH) presenting visible results in the first week of use. This product has scientific studies published in the European Journal of Dermatology and Venereology in 2024; in addition, more than 100,000 molecules were analyzed for its formulation, which took 18 years to create.
La Roche Posay launched MELAB3 to the Quifatex Sales Force and its collaborators. The objective is to make known the benefits and advantages of the product and thus deliver the most important information to all customers. The event included several activities in which Managers, Chiefs, Sales Team and the company's Internal Influencers participated, who will reinforce the message to their teams.
We thank the entire Quifatex team for their dedication and professionalism, as well as our clients for the trust placed in our health and wellness brands.
